Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Rosalaura V Villarreal-GonzalezNatalhie Acuña-Ortega

Abstract

Brentuximab vedotin is a monoclonal antibody drug conjugate used for the treatment of patients with Hodgkin lymphoma. Hypersensitivity reactions to brentuximab vedotin may include cutaneous, cardiovascular, respiratory, gastrointestinal and neurological signs and symptoms. We present the case of a 23-year-old Mexican female with stage IV progressive classical nodular sclerosing Hodgkin lymphoma who received multiple previous chemotherapy regimens. Brentuximab vedotin at 1.8 mg/kg (180 mg total dose), for 21-day cycles was indicated. Within 5 min of infusion of the 5th cycle of brentuximab, she developed severe anaphylaxis (hives, angioedema, diaphoresis, tachycardia, dyspnea, hypoxemia and loss of consciousness), which was successfully controlled with epinephrine, steroids and antihistamines.Management and outcome: Intradermal skin test at a concentration of 0.1 mg/ml was positive. Due to the severity of the symptoms and the lack of access to alternative treatments, we performed a desensitization protocol. A total of 180 mg of brentuximab was given in three bag solutions in 12 steps, with an initial concentration dose of 1/100 of the total dose in a course of 5.56 h with no hypersensitivity reactions. Severe anaphylaxis has bee...Continue Reading

References

Mar 11, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Violeta Régnier Galvão, Mariana C Castells
Apr 4, 2017·Immunology and Allergy Clinics of North America·Sheenal V Patel, David A Khan
Oct 3, 2017·Immunology and Allergy Clinics of North America·Rafael Bonamichi Santos, Violeta Régnier Galvão
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Mar 9, 2018·The Journal of Allergy and Clinical Immunology·Ghislaine Annie C IsabweMariana Castells
Apr 28, 2019·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·David Hong, David E Sloane
Jun 7, 2019·Current Opinion in Allergy and Clinical Immunology·Anna Sala-CunillVictoria Cardona

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Related Papers

Nature Reviews. Drug Discovery
Anas YounesPeter Kirkpatrick
Clinical Lymphoma, Myeloma & Leukemia
Amy E O'ConnellAnahita Dioun
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
R ChenEdward M Newman
© 2021 Meta ULC. All rights reserved